BioCentury | Oct 31, 2018
Distillery Therapeutics
Hepatic; renal
...liver disease (NAFLD) and acute kidney injury (AKI). In mouse primary hepatocytes, the ACMSD inhibitor TES-991...
...the ACMSD inhibitor TES-1025 decreased apoptosis. In a mouse model of diet-induced NAFLD, pretreatment with TES-991...
...include clinical testing of TES-1025 and TES-991 in NAFLD and AKI patients. TES Pharma has TES-991...
...the ACMSD inhibitor TES-1025 decreased apoptosis. In a mouse model of diet-induced NAFLD, pretreatment with TES-991...
...include clinical testing of TES-1025 and TES-991 in NAFLD and AKI patients. TES Pharma has TES-991...